A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7

作者：

Akaza, Hideyuki ^{[1
]}

Uemura, Hirotsugu ^{[2
]}

Tsukamoto, Taiji ^{[3
]}

Ozono, Seiichiro ^{[4
]}

Ogawa, Osamu ^{[5
]}

Sakai, Hideki ^{[6
]}

Oya, Mototsugu ^{[7
]}

Namiki, Mikio ^{[8
]}

Fukasawa, Satoshi ^{[9
]}

Yamaguchi, Akito ^{[10
]}

Uemura, Hiroji ^{[11
]}

Ohashi, Yasuo ^{[12
]}

Maeda, Hideki ^{[13
]}

Saito, Atsushi ^{[13
]}

Takeda, Kentaro ^{[13
]}

Naito, Seiji ^{[10
]}

机构：

[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan

[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan

[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan

[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan

[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan

[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan

[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan

[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期

关键词：

Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;

D O I：

10.1007/s10147-016-0952-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trial registration: ClinicalTrials.gov NCT01284920.

引用

页码：773 / 782

页数：10

共 50 条

[31] Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Matsubara, Nobuaki
Nagamori, Satsohi
Wakumoto, Yoshiaki
Uemura, Hirotsugu
Kimura, Go
Yokomizo, Akira
Kikukawa, Hiroaki
Mizokami, Atsushi
Kosaka, Takeo
Masumori, Naoya
Kawasaki, Yoshihide
Yonese, Junji
Nasu, Yasutomo
Fukasawa, Satoshi
Sugiyama, Takayuki
Kinuya, Seigo
Hosono, Makoto
Yamaguchi, Iku
Tsutsui, Hirokazu
Uemura, Hiroji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 173 - 180
[32] Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Sweeney, Christopher J.
Percent, Ivor J.
Babu, Sunil
Cultrera, Jennifer L.
Mehlhaff, Bryan A.
Goodman, Oscar B.
Morris, David S.
Schnadig, Ian D.
Albany, Costantine
Shore, Neal D.
Sieber, Paul R.
Guba, Susan C.
Zhang, Wei
Wacheck, Volker
Donoho, Gregory P.
Szpurka, Anna M.
Callies, Sophie
Lin, Boris Kin
Bendell, Johanna C.
CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2237 - 2247
[33] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
Serritella, Anthony
Shevrin, Daniel H.
Heath, Elisabeth I.
Wade, James Lloyd
Martinez, Elia
Karrison, Theodore
Stadler, Walter Michael
Szmulewitz, Russell Zelig
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[34] Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer
Shore, Neal D.
Schellhammer, Paul F.
Tutrone, Ronald F.
Mariados, Neil F.
Harrelson, Stacey S.
CLINICAL GENITOURINARY CANCER, 2020, 18 (05) : 416 - 422
[35] ENZALUTAMIDE ENHANCES GLYCOLYSIS IN CASTRATION-RESISTANT PROSTATE CANCER
Liu, Wang
Li, Jean
Artigues, Antonio
Yao, Si
Li, Benyi
JOURNAL OF UROLOGY, 2021, 206 : E741 - E741
[36] Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
Shiota, Masaki
LANCET ONCOLOGY, 2022, 23 (11): : 1345 - 1347
[37] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Rodriguez-Vida, Alejo
Galazi, Myria
Rudman, Sarah
Chowdhury, Simon
Sternberg, Cora N.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
[38] Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, Maha
Fizazi, Karim
Saad, Fred
Rathenborg, Per
Shore, Neal
Ferreira, Ubirajara
Ivashchenko, Petro
Demirhan, Eren
Modelska, Katharina
Phung, De
Krivoshik, Andrew
Sternberg, Cora N.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2465 - 2474
[39] Development of enzalutamide for metastatic castration-resistant prostate cancer
Bhattacharya, Suman
Hirmand, Mohammad
Phung, De
van Os, Steve
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
[40] Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg, Cora N.
Fizazi, Karim
Saad, Fred
Shore, Neal D.
De Giorgi, Ugo
Penson, David F.
Ferreira, Ubirajara
Efstathiou, Eleni
Madziarska, Katarzyna
Kolinsky, Michael P.
Cubero, Daniel I. G.
Noerby, Bettina
Zohren, Fabian
Lin, Xun
Modelska, Katharina
Sugg, Jennifer
Steinberg, Joyce
Hussain, Maha
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23): : 2197 - 2206

← 1 2 3 4 5 →